Sign in
Taking people in NetherlandsPhase 2

Imaging test for finding thyroid cancer spread in adults

Tests a PET scan using a radioactive tracer to detect thyroid cancer spread.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Rotterdam and Utrecht, NetherlandsSee the 2 sites
Registry title
[18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
1 Sept 2025
Expected to end
1 Dec 2027
Type of study
Interventional
Record updated
2 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with differentiated thyroid cancer. Some have newly found cancer in lymph nodes and are referred for surgery. Others are referred for 131I therapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Group 1: newly diagnosed differentiated thyroid cancer with lymph node metastases proven by pathology, referred for surgery. Group 2: differentiated thyroid cancer referred for 131I therapy.
Earlier treatment
Cannot have had iodine (for example iodinated contrast agent) or perchlorate within the past 2 months.

Main reasons for not taking part

  • Mentally or legally incapacitated
  • Pregnant or breastfeeding
  • Iodine or perchlorate exposure within the past 2 months
  • Takes lithium
  • Takes amiodarone

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Group 1: patients with newly diagnosed differentiated thyroid cancer and pathologically proven lymph node metastases thyroid cancer referred for surgical resection - Group 2: patients with differentiated thyroid cancer referred for 131I therapy - The patient has provided written informed consent authorization before participating in the study - The patient is ≥ 18 years old - The patient has an ECOG status grade 0-2

Who cannot take part

  • Patient is mentally or legally incapacitated - Patient is pregnant or lactating - Patient has been subjected to an excess of substrates of the sodium iodine symporter such as iodine (e.g. in the form of iodinated contrast agent) or perchlorate within the past 2 months. - Patient takes lithium - Patient takes amiodarone

Where in Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
  • Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people

About the trial

What the trial wants to find out

a) To determine the optimal time point acquisition of [18F]TFB PET/CT, b) to determine the value of [18F]TFB PET/CT for detection of (pre-operative) metastatic lymph node(s) in patients with differentiated thyroid cancer and c) to determine the value of [18F]TFB PET/CT for the estimation of radioiodine therapy response in patients with persistent and recurrent differentiated thyroid cancer.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
[18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study
Plain-language title
Imaging test for finding thyroid cancer spread in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
2 April 2025